OC
LXRX icon

Oppenheimer & Co’s Lexicon Pharmaceuticals LXRX Stock Holding History

Oppenheimer & Co’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,500
Closed -$36.7K – 1811
2026
Q1 		$36.7K Hold
23,500
– – ﹤0.01% 1671
2025
Q4 		$27K Hold
23,500
– – ﹤0.01% 1520
2025
Q3 		$31.7K Hold
23,500
– – ﹤0.01% 1636
2025
Q2 		$22.2K Buy
23,500
+3,400
+17% +$2.2K ﹤0.01% 1593
2025
Q1 		$9.26K Buy
+20,100
New +$12.7K ﹤0.01% 1562
2024
Q1 		– Sell
-24,500
Closed -$37.5K – 1483
2023
Q4 		$37.5K Buy
+24,500
New +$29.1K ﹤0.01% 1360

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Oppenheimer & Co's LXRX Position: Q2 2026 in Review

Oppenheimer & Co sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2026, closing a stake of 23,500 shares — an estimated $36.7K sold.

Oppenheimer & Co first reported a position in LXRX in Q4 2023 and held it in 6 quarters. The position peaked at $37.5K in Q4 2023. 148 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Oppenheimer & Co reported no remaining Lexicon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Oppenheimer & Co sold 23,500 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $36.7K.
  • Oppenheimer & Co first reported a position in Lexicon Pharmaceuticals in Q4 2023 and held it in 6 quarters.
  • Oppenheimer & Co's Lexicon Pharmaceuticals position peaked at $37.5K in Q4 2023.
  • 148 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.